0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Non-invasive Vaccine Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-36E12384
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Non invasive Vaccine Market Research Report 2022
BUY CHAPTERS

Global Non-invasive Vaccine Market Research Report 2025

Code: QYRE-Auto-36E12384
Report
February 2025
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Non-invasive Vaccine Market Size

The global market for Non-invasive Vaccine was valued at US$ 2961 million in the year 2024 and is projected to reach a revised size of US$ 4313 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Non-invasive Vaccine Market

Non-invasive Vaccine Market

Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-invasive Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-invasive Vaccine.
The Non-invasive Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-invasive Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-invasive Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Non-invasive Vaccine Market Report

Report Metric Details
Report Name Non-invasive Vaccine Market
Accounted market size in year US$ 2961 million
Forecasted market size in 2031 US$ 4313 million
CAGR 5.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Public
  • Private
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological, EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals, AstraZeneca, Cipla, BCHT
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Non-invasive Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Non-invasive Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Non-invasive Vaccine Market growing?

Ans: The Non-invasive Vaccine Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Non-invasive Vaccine Market size in 2031?

Ans: The Non-invasive Vaccine Market size in 2031 will be US$ 4313 million.

Who are the main players in the Non-invasive Vaccine Market report?

Ans: The main players in the Non-invasive Vaccine Market are Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol, PaxVax, Vabiotech, Tiantan Biological, EuBiologics, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals, AstraZeneca, Cipla, BCHT

What are the Application segmentation covered in the Non-invasive Vaccine Market report?

Ans: The Applications covered in the Non-invasive Vaccine Market report are Public, Private

What are the Type segmentation covered in the Non-invasive Vaccine Market report?

Ans: The Types covered in the Non-invasive Vaccine Market report are Oral Vaccine, Nasal Spray Vaccine

Recommended Reports

Vaccine Delivery & Devices

Types of Vaccines

Specific Vaccine Markets

1 Non-invasive Vaccine Market Overview
1.1 Product Definition
1.2 Non-invasive Vaccine by Type
1.2.1 Global Non-invasive Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Oral Vaccine
1.2.3 Nasal Spray Vaccine
1.3 Non-invasive Vaccine by Application
1.3.1 Global Non-invasive Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Public
1.3.3 Private
1.4 Global Non-invasive Vaccine Market Size Estimates and Forecasts
1.4.1 Global Non-invasive Vaccine Revenue 2020-2031
1.4.2 Global Non-invasive Vaccine Sales 2020-2031
1.4.3 Global Non-invasive Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Non-invasive Vaccine Market Competition by Manufacturers
2.1 Global Non-invasive Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Non-invasive Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Non-invasive Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Non-invasive Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Non-invasive Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Non-invasive Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Non-invasive Vaccine, Date of Enter into This Industry
2.8 Global Non-invasive Vaccine Market Competitive Situation and Trends
2.8.1 Global Non-invasive Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Non-invasive Vaccine Players Market Share by Revenue
2.8.3 Global Non-invasive Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Non-invasive Vaccine Market Scenario by Region
3.1 Global Non-invasive Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Non-invasive Vaccine Sales by Region: 2020-2031
3.2.1 Global Non-invasive Vaccine Sales by Region: 2020-2025
3.2.2 Global Non-invasive Vaccine Sales by Region: 2026-2031
3.3 Global Non-invasive Vaccine Revenue by Region: 2020-2031
3.3.1 Global Non-invasive Vaccine Revenue by Region: 2020-2025
3.3.2 Global Non-invasive Vaccine Revenue by Region: 2026-2031
3.4 North America Non-invasive Vaccine Market Facts & Figures by Country
3.4.1 North America Non-invasive Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Non-invasive Vaccine Sales by Country (2020-2031)
3.4.3 North America Non-invasive Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Non-invasive Vaccine Market Facts & Figures by Country
3.5.1 Europe Non-invasive Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Non-invasive Vaccine Sales by Country (2020-2031)
3.5.3 Europe Non-invasive Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Non-invasive Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Non-invasive Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Non-invasive Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Non-invasive Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Non-invasive Vaccine Market Facts & Figures by Country
3.7.1 Latin America Non-invasive Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Non-invasive Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Non-invasive Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Non-invasive Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Non-invasive Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Non-invasive Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Non-invasive Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Non-invasive Vaccine Sales by Type (2020-2031)
4.1.1 Global Non-invasive Vaccine Sales by Type (2020-2025)
4.1.2 Global Non-invasive Vaccine Sales by Type (2026-2031)
4.1.3 Global Non-invasive Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Non-invasive Vaccine Revenue by Type (2020-2031)
4.2.1 Global Non-invasive Vaccine Revenue by Type (2020-2025)
4.2.2 Global Non-invasive Vaccine Revenue by Type (2026-2031)
4.2.3 Global Non-invasive Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Non-invasive Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Non-invasive Vaccine Sales by Application (2020-2031)
5.1.1 Global Non-invasive Vaccine Sales by Application (2020-2025)
5.1.2 Global Non-invasive Vaccine Sales by Application (2026-2031)
5.1.3 Global Non-invasive Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Non-invasive Vaccine Revenue by Application (2020-2031)
5.2.1 Global Non-invasive Vaccine Revenue by Application (2020-2025)
5.2.2 Global Non-invasive Vaccine Revenue by Application (2026-2031)
5.2.3 Global Non-invasive Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Non-invasive Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Non-invasive Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Non-invasive Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Non-invasive Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Company Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Lanzhou Institute Non-invasive Vaccine Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Company Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Serum Institute Non-invasive Vaccine Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Company Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Valneva Non-invasive Vaccine Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.7.1 Shanghai United Cell Company Information
6.7.2 Shanghai United Cell Description and Business Overview
6.7.3 Shanghai United Cell Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Shanghai United Cell Non-invasive Vaccine Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Company Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bibcol Non-invasive Vaccine Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Company Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 PaxVax Non-invasive Vaccine Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Company Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Vabiotech Non-invasive Vaccine Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Company Information
6.11.2 Tiantan Biological Description and Business Overview
6.11.3 Tiantan Biological Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Tiantan Biological Non-invasive Vaccine Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Company Information
6.12.2 EuBiologics Description and Business Overview
6.12.3 EuBiologics Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 EuBiologics Non-invasive Vaccine Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Company Information
6.13.2 Panacea Biotec Ltd Description and Business Overview
6.13.3 Panacea Biotec Ltd Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Panacea Biotec Ltd Non-invasive Vaccine Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Company Information
6.14.2 Bio-Med Description and Business Overview
6.14.3 Bio-Med Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Bio-Med Non-invasive Vaccine Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Company Information
6.15.2 Halfkin Bio-Pharmaceuticals Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
6.16 AstraZeneca
6.16.1 AstraZeneca Company Information
6.16.2 AstraZeneca Description and Business Overview
6.16.3 AstraZeneca Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 AstraZeneca Non-invasive Vaccine Product Portfolio
6.16.5 AstraZeneca Recent Developments/Updates
6.17 Cipla
6.17.1 Cipla Company Information
6.17.2 Cipla Description and Business Overview
6.17.3 Cipla Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Cipla Non-invasive Vaccine Product Portfolio
6.17.5 Cipla Recent Developments/Updates
6.18 BCHT
6.18.1 BCHT Company Information
6.18.2 BCHT Description and Business Overview
6.18.3 BCHT Non-invasive Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.18.4 BCHT Non-invasive Vaccine Product Portfolio
6.18.5 BCHT Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Non-invasive Vaccine Industry Chain Analysis
7.2 Non-invasive Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Non-invasive Vaccine Production Mode & Process Analysis
7.4 Non-invasive Vaccine Sales and Marketing
7.4.1 Non-invasive Vaccine Sales Channels
7.4.2 Non-invasive Vaccine Distributors
7.5 Non-invasive Vaccine Customer Analysis
8 Non-invasive Vaccine Market Dynamics
8.1 Non-invasive Vaccine Industry Trends
8.2 Non-invasive Vaccine Market Drivers
8.3 Non-invasive Vaccine Market Challenges
8.4 Non-invasive Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Non-invasive Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Non-invasive Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Non-invasive Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Non-invasive Vaccine Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Non-invasive Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Non-invasive Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Non-invasive Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Non-invasive Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Non-invasive Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Non-invasive Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Non-invasive Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Non-invasive Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Non-invasive Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-invasive Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Non-invasive Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Non-invasive Vaccine Sales by Region (2020-2025) & (K Units)
 Table 18. Global Non-invasive Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Non-invasive Vaccine Sales by Region (2026-2031) & (K Units)
 Table 20. Global Non-invasive Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Non-invasive Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Non-invasive Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Non-invasive Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Non-invasive Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Non-invasive Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Non-invasive Vaccine Sales by Country (2020-2025) & (K Units)
 Table 27. North America Non-invasive Vaccine Sales by Country (2026-2031) & (K Units)
 Table 28. North America Non-invasive Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Non-invasive Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Non-invasive Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Non-invasive Vaccine Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Non-invasive Vaccine Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Non-invasive Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Non-invasive Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Non-invasive Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Non-invasive Vaccine Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Non-invasive Vaccine Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Non-invasive Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Non-invasive Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Non-invasive Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Non-invasive Vaccine Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Non-invasive Vaccine Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Non-invasive Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Non-invasive Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Non-invasive Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Non-invasive Vaccine Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Non-invasive Vaccine Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Non-invasive Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Non-invasive Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Non-invasive Vaccine Sales (K Units) by Type (2020-2025)
 Table 51. Global Non-invasive Vaccine Sales (K Units) by Type (2026-2031)
 Table 52. Global Non-invasive Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Non-invasive Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Non-invasive Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Non-invasive Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Non-invasive Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Non-invasive Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Non-invasive Vaccine Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Non-invasive Vaccine Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Non-invasive Vaccine Sales (K Units) by Application (2020-2025)
 Table 61. Global Non-invasive Vaccine Sales (K Units) by Application (2026-2031)
 Table 62. Global Non-invasive Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Non-invasive Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Non-invasive Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Non-invasive Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Non-invasive Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Non-invasive Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Non-invasive Vaccine Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Non-invasive Vaccine Price (US$/Unit) by Application (2026-2031)
 Table 70. Merck Company Information
 Table 71. Merck Description and Business Overview
 Table 72. Merck Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Merck Non-invasive Vaccine Product
 Table 74. Merck Recent Developments/Updates
 Table 75. GSK Company Information
 Table 76. GSK Description and Business Overview
 Table 77. GSK Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. GSK Non-invasive Vaccine Product
 Table 79. GSK Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Sanofi Non-invasive Vaccine Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. Lanzhou Institute Company Information
 Table 86. Lanzhou Institute Description and Business Overview
 Table 87. Lanzhou Institute Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Lanzhou Institute Non-invasive Vaccine Product
 Table 89. Lanzhou Institute Recent Developments/Updates
 Table 90. Serum Institute Company Information
 Table 91. Serum Institute Description and Business Overview
 Table 92. Serum Institute Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Serum Institute Non-invasive Vaccine Product
 Table 94. Serum Institute Recent Developments/Updates
 Table 95. Valneva Company Information
 Table 96. Valneva Description and Business Overview
 Table 97. Valneva Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Valneva Non-invasive Vaccine Product
 Table 99. Valneva Recent Developments/Updates
 Table 100. Shanghai United Cell Company Information
 Table 101. Shanghai United Cell Description and Business Overview
 Table 102. Shanghai United Cell Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Shanghai United Cell Non-invasive Vaccine Product
 Table 104. Shanghai United Cell Recent Developments/Updates
 Table 105. Bibcol Company Information
 Table 106. Bibcol Description and Business Overview
 Table 107. Bibcol Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Bibcol Non-invasive Vaccine Product
 Table 109. Bibcol Recent Developments/Updates
 Table 110. PaxVax Company Information
 Table 111. PaxVax Description and Business Overview
 Table 112. PaxVax Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. PaxVax Non-invasive Vaccine Product
 Table 114. PaxVax Recent Developments/Updates
 Table 115. Vabiotech Company Information
 Table 116. Vabiotech Description and Business Overview
 Table 117. Vabiotech Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Vabiotech Non-invasive Vaccine Product
 Table 119. Vabiotech Recent Developments/Updates
 Table 120. Tiantan Biological Company Information
 Table 121. Tiantan Biological Description and Business Overview
 Table 122. Tiantan Biological Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Tiantan Biological Non-invasive Vaccine Product
 Table 124. Tiantan Biological Recent Developments/Updates
 Table 125. EuBiologics Company Information
 Table 126. EuBiologics Description and Business Overview
 Table 127. EuBiologics Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. EuBiologics Non-invasive Vaccine Product
 Table 129. EuBiologics Recent Developments/Updates
 Table 130. Panacea Biotec Ltd Company Information
 Table 131. Panacea Biotec Ltd Description and Business Overview
 Table 132. Panacea Biotec Ltd Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Panacea Biotec Ltd Non-invasive Vaccine Product
 Table 134. Panacea Biotec Ltd Recent Developments/Updates
 Table 135. Bio-Med Company Information
 Table 136. Bio-Med Description and Business Overview
 Table 137. Bio-Med Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Bio-Med Non-invasive Vaccine Product
 Table 139. Bio-Med Recent Developments/Updates
 Table 140. Halfkin Bio-Pharmaceuticals Company Information
 Table 141. Halfkin Bio-Pharmaceuticals Description and Business Overview
 Table 142. Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Product
 Table 144. Halfkin Bio-Pharmaceuticals Recent Developments/Updates
 Table 145. AstraZeneca Company Information
 Table 146. AstraZeneca Description and Business Overview
 Table 147. AstraZeneca Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. AstraZeneca Non-invasive Vaccine Product
 Table 149. AstraZeneca Recent Developments/Updates
 Table 150. Cipla Company Information
 Table 151. Cipla Description and Business Overview
 Table 152. Cipla Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Cipla Non-invasive Vaccine Product
 Table 154. Cipla Recent Developments/Updates
 Table 155. BCHT Company Information
 Table 156. BCHT Description and Business Overview
 Table 157. BCHT Non-invasive Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. BCHT Non-invasive Vaccine Product
 Table 159. BCHT Recent Developments/Updates
 Table 160. Key Raw Materials Lists
 Table 161. Raw Materials Key Suppliers Lists
 Table 162. Non-invasive Vaccine Distributors List
 Table 163. Non-invasive Vaccine Customers List
 Table 164. Non-invasive Vaccine Market Trends
 Table 165. Non-invasive Vaccine Market Drivers
 Table 166. Non-invasive Vaccine Market Challenges
 Table 167. Non-invasive Vaccine Market Restraints
 Table 168. Research Programs/Design for This Report
 Table 169. Key Data Information from Secondary Sources
 Table 170. Key Data Information from Primary Sources
 Table 171. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Non-invasive Vaccine
 Figure 2. Global Non-invasive Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Non-invasive Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Oral Vaccine Product Picture
 Figure 5. Nasal Spray Vaccine Product Picture
 Figure 6. Global Non-invasive Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Non-invasive Vaccine Market Share by Application: 2024 & 2031
 Figure 8. Public
 Figure 9. Private
 Figure 10. Global Non-invasive Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Non-invasive Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Non-invasive Vaccine Sales (2020-2031) & (K Units)
 Figure 13. Global Non-invasive Vaccine Average Price (US$/Unit) & (2020-2031)
 Figure 14. Non-invasive Vaccine Report Years Considered
 Figure 15. Non-invasive Vaccine Sales Share by Manufacturers in 2024
 Figure 16. Global Non-invasive Vaccine Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Non-invasive Vaccine Players: Market Share by Revenue in Non-invasive Vaccine in 2024
 Figure 18. Non-invasive Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Non-invasive Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Non-invasive Vaccine Sales Market Share by Country (2020-2031)
 Figure 21. North America Non-invasive Vaccine Revenue Market Share by Country (2020-2031)
 Figure 22. United States Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Non-invasive Vaccine Sales Market Share by Country (2020-2031)
 Figure 25. Europe Non-invasive Vaccine Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Non-invasive Vaccine Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Non-invasive Vaccine Revenue Market Share by Region (2020-2031)
 Figure 33. China Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America Non-invasive Vaccine Sales Market Share by Country (2020-2031)
 Figure 41. Latin America Non-invasive Vaccine Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Middle East and Africa Non-invasive Vaccine Sales Market Share by Country (2020-2031)
 Figure 46. Middle East and Africa Non-invasive Vaccine Revenue Market Share by Country (2020-2031)
 Figure 47. Turkey Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. UAE Non-invasive Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Global Sales Market Share of Non-invasive Vaccine by Type (2020-2031)
 Figure 51. Global Revenue Market Share of Non-invasive Vaccine by Type (2020-2031)
 Figure 52. Global Non-invasive Vaccine Price (US$/Unit) by Type (2020-2031)
 Figure 53. Global Sales Market Share of Non-invasive Vaccine by Application (2020-2031)
 Figure 54. Global Revenue Market Share of Non-invasive Vaccine by Application (2020-2031)
 Figure 55. Global Non-invasive Vaccine Price (US$/Unit) by Application (2020-2031)
 Figure 56. Non-invasive Vaccine Value Chain
 Figure 57. Channels of Distribution (Direct Vs Distribution)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network